Peptide Bioregulators: The Khavinson Family

What Bioregulators Actually Are

The bioregulator story starts in Soviet-era laboratories in the 1970s and 1980s. Researchers isolated peptide-rich fractions from animal organs — thymus, pineal gland, brain cortex, prostate, blood vessels — and reported that these fractions, administered back into aged or damaged animals, appeared to support the corresponding tissue. Those crude extract preparations became a class of products the Russian literature calls cytamins: Thymalin from thymus, Epithalamin from pineal, Cortexin from brain cortex, Prostatilen from prostate.

The next step is where the modern "bioregulator" family comes from. The Khavinson group analyzed the amino-acid composition of the active extract fractions and synthesized ultrashort peptides meant to reproduce the tissue-specific effect in a defined, single-molecule form. Thymalin gave rise to the dipeptide Thymogen (Glu-Trp); the pineal extract gave rise to Epitalon (Ala-Glu-Asp-Gly); the cortex extract gave rise to Cortagen (Ala-Glu-Asp-Pro); and so on. The synthetic peptides are the products sold today as research chemicals.

Two features define the family and set expectations for the evidence. First, it is overwhelmingly a single-lab body of work — most primary studies trace back to the St. Petersburg group and its collaborators, and independent Western replication is close to nonexistent. Second, the human and clinical history is old and largely Russian, and it mostly belongs to the extracts, not to the synthetic peptides. Neither of those facts makes the work wrong. They do mean that every efficacy statement below should be read as what the originating researchers reported, not as an established, reproduced result.

The Gene-Expression Hypothesis — Read It As A Hypothesis

The mechanism proposed for the whole family is the same, and it is the intellectual heart of the bioregulator concept: the originating group hypothesizes that these ultrashort peptides act as gene-expression regulators. In this framework, a peptide small enough to enter cells (and, the group argues, the nucleus) can interact with regulatory regions of DNA or with chromatin and shift the transcription of specific genes in the tissue the peptide was derived from. A cortex-derived peptide would preferentially act on nervous tissue; a thymus-derived peptide on immune tissue.

The direct support for this idea is molecular and preclinical. Studies from the group have reported that specific short peptides bind DNA and alter gene expression in cell culture — for example, work on the tetrapeptide KEDG (the Testagen sequence) reported peptide-driven changes in gene activity in a human cell line (PMID 22117547). Broader reviews and mechanistic papers from the same lineage have framed these peptides as epigenetic regulators that influence transcription and protein synthesis (PMID 27909961, PMID 34834147).

Two honest caveats belong on this hypothesis every time it is invoked. It is built almost entirely on in-vitro and rodent data, so the leap from "this peptide shifts transcription in a dish" to "this peptide rejuvenates an organ in a person" is exactly that — a leap the primary data does not complete. And it is single-source: the model, the assays and most of the confirming experiments come from one research tradition. A mechanism that has not been stress-tested by independent labs is a promising hypothesis, not an established pathway.

Extract vs Synthetic — The Family's Central Honesty Point

If a reader takes one thing from this page, it should be this distinction, because nearly every misleading claim about bioregulators lives in the gap between the two.

The tissue extracts (the cytamins) are complex, multi-component preparations pulled from animal organs. They are what Russian clinicians actually used, sometimes for decades, and so they carry whatever real human track record the family has. Thymalin (thymus extract) and Prostatilen (prostate extract) have the deepest clinical literature — Prostatilen has published human data in chronic prostatitis and benign prostatic conditions (PMID 36318852).

The synthetic short peptides are single, defined molecules designed from those extracts. They are cleaner, reproducible and what vendors ship — but in most cases they do not inherit the extract's human data. Cortagen is not Cortexin. Thymogen is not Thymalin. Prostamax is not Prostatilen. The synthetic version has to earn its own evidence, and for most of the family that evidence stops at cell culture and rodents.

This is why marketing that borrows the extract's clinical reputation for the synthetic peptide in the vial is the single most common distortion in this space. When a product page for a synthetic tetrapeptide cites "decades of clinical use," that history almost always belongs to the extract. Carry that question — is this claim about the extract or about the synthetic peptide? — into every row below.

The Bioregulator Family At A Glance

The table maps the family members already covered on this site. "Evidence level" refers to the synthetic peptide unless noted, and reflects the honest ceiling of the published work — mostly preclinical, single-lab. The extract parent column shows where the deeper human history actually sits.

A few honest notes on the table. Thymulin is included because it is often shelved next to this family and shares the thymic theme, but it is a distinct, endogenous zinc-dependent thymic hormone — not a Khavinson synthetic short peptide — and it has its own evidence base. Vilon (KE) is a dipeptide whose geroprotection and immune claims are preclinical and unreplicated. Cardiogen (AEDR) is the cardiac member of the family; its sequence is verified and it appears in a small amount of compound-specific review and cell-transport work from the Khavinson group, but that evidence is thin and mechanistic — no human trials. One name that circulates in vendor catalogs — "Cerebro Protein" (a porcine brain hydrolysate, unrelated to this family) — is deliberately left off, because it does not belong to the Khavinson bioregulator family in any meaningful evidentiary sense.

The Family, Compound By Compound

The rest of this guide walks each compound and points to its full cluster of deep-dive articles. The pattern repeats: a synthetic sequence, a tissue target, an extract parent that holds the human reputation, and a preclinical evidence base that is usually thinner than the marketing implies.

The Immune Cluster — Thymalin, Thymogen, Vilon

The thymus branch is the most clinically credible corner of the family, and it is the clearest illustration of the extract-vs-synthetic split.

Thymalin is the extract — a thymic polypeptide preparation with the longest Russian clinical history in the whole family, studied for immune balance and age-related immune decline. It is distinct from both thymulin and thymosin alpha-1. Its reputation is real but old and largely single-tradition; the Thymalin benefits and Thymalin dosing guide articles work through what that literature actually reported and where it stops.

Thymogen (Glu-Trp) is the dipeptide isolated and synthesized from Thymalin, and it is the best-evidenced synthetic peptide in the family. Khavinson-group and collaborator studies reported immune-modulating effects in rodents and in Russian single-group clinical settings (PMID 11707921, PMID 9637345). "Best-evidenced synthetic" is a relative statement — the data is still single-lab and mostly uncontrolled by modern standards. See the Thymogen benefits and Thymogen dosing guide clusters for the full read.

Vilon (Lys-Glu) is a dipeptide bioregulator studied in rodent and cell models for immune and geroprotective effects. The group reported changes in immune parameters and gene expression in aged animals (PMID 10944717, PMID 23486604), but there is no independent human trial and no Western replication. The Vilon benefits and Vilon dosing guide articles keep those claims tied to their preclinical, originator-group source.

The Longevity Cluster — Epitalon, Pinealon

The pineal branch is where the family's boldest claims live, and where the "read it as a claim" discipline matters most.

Epitalon (Ala-Glu-Asp-Gly) is the synthetic analog of the pineal extract Epithalamin and the most-studied peptide in the family for the geroprotection hypothesis. The originating group has reported effects on telomerase and lifespan in animals, and — most famously — reduced mortality in human observational cohorts. Those human figures come from single-group, uncontrolled cohorts with overlapping populations and implausibly large reported effect sizes (PMID 14523363); they are best read as the originators' claims, not as demonstrated longevity benefits. The Epitalon benefits and Epitalon dosing guide clusters frame the telomere and lifespan reputation against that limitation.

Pinealon (Glu-Asp-Arg) is a brain-peptide bioregulator marketed for neuroprotection. The evidence is cell-culture and rodent only — reported effects on neuron survival and oxidative stress in preclinical models — with no human trials. The Pinealon benefits and Pinealon dosing guide articles keep that ceiling explicit.

The Neuro Cluster — Cortagen, Cartalax

Cortagen (Ala-Glu-Asp-Pro) is the synthetic analog of the brain-cortex extract Cortexin, and its reputation centers on nerve repair. That reputation rests on a narrow base: a Khavinson-group rat study reported accelerated regeneration of a surgically injured sciatic nerve (PMID 11276314), and a microarray study reported that Cortagen shifted the expression of roughly 110 genes in mouse tissue (PMID 15159690). The clinical track record belongs to the Cortexin extract, not to the synthetic peptide. The full picture is in Cortagen benefits and the Cortagen dosing guide. Note that Cortagen is not connected to the retinopathy data sometimes attributed to it — that work involves different sequences.

Cartalax (Ala-Glu-Asp) is the AED tripeptide studied in preclinical cell models for cartilage and connective-tissue gene regulation. Its evidence base is in-vitro only. The Cartalax benefits and Cartalax dosing guide articles report what the cell-model work described without extending it to joint outcomes in people.

Cardiogen (Ala-Glu-Asp-Arg) is the cardiac member of the family. The compound-specific evidence is thin and mechanistic: a Khavinson-group review described the AEDR tetrapeptide among peptides that regulate molecules involved in cardiovascular-cell inflammaging and the senescence-associated secretory phenotype (PMID 36611900), and a later paper modeled how ultrashort peptides like it are transported into cells (PMID 36979488). There are no human trials, so the "heart support" framing is hypothesis, not demonstrated outcome. The Cardiogen benefits and Cardiogen dosing guide articles keep that ceiling explicit.

The Respiratory Cluster — Bronchogen

Bronchogen (Ala-Glu-Asp-Leu) is the bronchial tetrapeptide studied in rat lung models. Group and collaborator studies reported effects in rat models of chronic obstructive pulmonary disease and in-vitro respiratory-tissue differentiation (PMID 26468022, PMID 30199201). There is no human data for the synthetic peptide. The Bronchogen benefits and Bronchogen dosing guide clusters keep the respiratory claims tied to their preclinical, rat-model source.

The Reproductive And Glandular Cluster — Testagen, Prostamax

These two are the family's clearest cautionary cases, because their names imply outcomes their evidence does not support.

Testagen (Lys-Glu-Asp-Gly) is a testis-derived tetrapeptide marketed for reproductive-tissue support. The critical honesty point: it contains no steroid and is unrelated to testosterone, despite the name. It is distinct from the Testoluten extract, and there is no verified reproductive-outcome study for the synthetic peptide — the primary support is the gene-expression mechanism work on the KEDG sequence in cell culture (PMID 22117547). The Testagen benefits and Testagen dosing guide articles make the "not testosterone" point front and center.

Prostamax (Lys-Glu-Asp-Pro) is a prostate tetrapeptide. The synthetic peptide has minimal direct evidence — the primary study concerns chromatin-level activity, not a prostate outcome. The prostate clinical data that vendors invoke belongs to the Prostatilen extract, which does have published human data in prostatitis and benign prostatic conditions (PMID 36318852) — but that is the extract, not synthetic Prostamax. The Prostamax benefits and Prostamax dosing guide clusters keep that line sharp.

The Adjacent Case — Thymulin

Thymulin rounds out the thymic theme but sits apart from the Khavinson synthetics. It is an endogenous zinc-dependent nonapeptide hormone produced by thymic epithelial cells, and its activity is absolutely zinc-dependent. It has its own, more conventional evidence base and is not a reverse-engineered extract peptide. It is included here only because it is frequently grouped with the immune bioregulators; the Thymulin benefits article treats it on its own terms.

How To Read This Family Without Getting Sold

A few principles fall out of everything above, and they apply to every compound in the table:

Ask which thing the claim is about. Extract or synthetic peptide? A clinical-sounding claim attached to a synthetic research chemical usually borrows the extract's reputation. That single question filters out most of the misleading marketing.

Treat "single-lab" as a real limitation, not a footnote. A mechanism and a set of outcomes that have never been independently reproduced remain a hypothesis. The bioregulator literature is interesting precisely because it is unusual — and unusual claims need outside replication before they harden into fact.

Discount the longevity numbers. The most dramatic human figures in this family come from uncontrolled, overlapping observational cohorts with implausible effect sizes. They are the originators' claims. They are not evidence that any of these peptides extends human lifespan.

Verify the actual molecule. Because these are sold as research chemicals, sequence identity and third-party testing matter more here than almost anywhere else — a "KEDG" or "AEDL" label on a vial is only as good as the certificate of analysis behind it. For buyer-stage detail, each cluster's buying guide (for example the Cortagen buying guide or Thymalin buying guide) works through COA and sequence-verification questions rather than dose.

Bioregulators are one of the most conceptually interesting families in the research-peptide world, and also one of the easiest to oversell. The honest position is narrow: an intriguing, largely preclinical, single-lab body of work, with a real but old extract history that mostly does not transfer to the synthetic peptides people actually buy.

Related Guides

• Cortagen Benefits: What The Rat Data Shows — the neuro branch, evidence and extract caveat
• Thymogen Dosing Guide — the best-evidenced synthetic, with honest dose provenance
• Thymalin Benefits — the extract with the deepest clinical history
• Epitalon Benefits — the geroprotection reputation against its cohort limitations
• Vilon Dosing Guide — the immune/geroprotection dipeptide
• Pinealon Benefits — the neuroprotection claims and their preclinical ceiling
• Bronchogen Benefits — the respiratory branch, rat-model only
• Testagen Benefits — why the name is misleading (not testosterone)
• Prostamax Benefits — synthetic peptide vs the Prostatilen extract
• Cartalax Benefits — the cartilage/connective-tissue tripeptide

References